Navigation Links
Isis Announces $4.2 Million in Government Contracts Awarded to Its Ibis Subsidiary for Biodefense Applications Development
Date:9/20/2007

rity (DHS), and others.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 17 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing drugs for a wide variety of diseases. Ibis Biosciences, Inc., Isis' wholly owned subsidiary, is developing and commercializing the Ibis T5000(TM) Biosensor System, a revolutionary system to identify infectious organisms. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at http://www.isispharm.com.

This press release includes forward-looking statements regarding the development and commercialization of the Ibis T5000 Biosensor System, Ibis' technology, and the revenue potential of certain government contracts. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' goals or projections. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, in developing and commercializing systems to identify infectious organisms that are effective and commercially attractive, and in the endeavor of building a business around such products. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... May 4, 2015 GliaCure, a privately-held ... therapies for neurological and neuropsychiatric disorders based on ... of Alzheimer,s patients in a Phase 1b clinical ... compound developed as a potential disease-modifying treatment. GliaCure,s ... in that it both promotes the clearance of ...
(Date:5/4/2015)... TEL AVIV, Israel , May 4, 2015 /PRNewswire/ ... has filed its annual report on Form 20-F for ... U.S. Securities and Exchange Commission ("SEC"). The annual report ... for the development of antibodies in the area of ... antibodies with superior qualities of high specificity and binding ...
(Date:5/4/2015)... , May 4, 2015  Traverse Biosciences ... cooperative research and development agreement (CRADA) with Aratana ... the development of TRB-N0224 for the treatment and ... dogs and cats.  Traverse Biosciences has also granted ... the treatment and control of periodontal disease in ...
(Date:5/4/2015)... - Fluorinov Pharma (Fluorinov), a FACIT portfolio company, ... Roger J Garceau, to its Board of Directors. ... including corporate development and clinical strategy, his appointment ... expertise as Fluorinov transitions to clinical development.  ... pharmaceutical development experience to Fluorinov and most recently ...
Breaking Biology Technology:GliaCure Initiates Phase 1b Dosing in Alzheimer's Patients 2Tikcro Technologies Files Annual Report on Form 20-F for the Year Ended December 31, 2014 2Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 2Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 3Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 4Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 3
... ... analysis has become a standard tool in the chemical and pharmaceutical industries ... reactions during the development and scale-up of chemical processes. METTLER TOLEDO ... Chemical Processes Using Real-Time In Situ FTIR Analytics as a Process Analytical ...
... ... for Laboratory Accreditation (A2LA) and was assigned certificate number 1.01 thirty years ago. ... (Vocus) November 3, ... the American Association for Laboratory Accreditation (A2LA) and was assigned certificate number ...
... 3 Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a ... the third quarter ended September 30, 2009, and provided a ... the 320th event target in our pivotal Phase 3 SPEAR ... cell lung cancer. This event allowed us to collect ...
Cached Biology Technology:Development of Batch and Continuous Chemical Processes Using Real-Time In Situ FTIR Analytics as a Process Analytical Technology (PAT) Tool 2Lancaster Laboratories -- First Lab to be A2LA Accredited for 30 Consecutive Years 2Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 2Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 3Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 4Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 5Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 6Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 7
(Date:4/27/2015)... 27, 2015  For more than four decades, AUVSI,s ... been the premier worldwide event for the unmanned land, ... must-attend event for any local, national, or trade news ... commercial markets and current applications of unmanned technologies. The ... projected $48 billion industry, and how it will soon ...
(Date:4/27/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces that its Wocket® Smart ... week of May, 2015 and will be fulfilling all ... Gino Pereira , Chief Executive Officer said, ... Wocket® enters the consumer market. We would like to ...
(Date:4/27/2015)... Profile Solutions, Inc. (OTC: PSIQ), a leading ... pleased to announce that Dr Gerry Bedore ... of its scientific advisory board. ... leader in technology-enhanced learning models. He was a co-founder ... studies and books focused on online student success and ...
Breaking Biology News(10 mins):UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... may be ignoring a desire by American consumers to dine ... Researchers found that more than 8 out of 10 ... to pay more to dine at "green" restaurants. More than ... to protect the environment. The only problem is that ...
... Known nationally for her research into single-cell organisms that ... of microbiology and molecular genetics at The University of ... selected to receive the 2011 American Society for Microbiology ... members who have made significant contributions to the society. ...
... Pennsylvania, Dr. Ron Koder, assistant professor of physics at The ... that devised a novel method for producing an artificial protein ... was recently awarded a three-year $1.3 million grant from the ... can be administered to injured troops on the battlefield. ...
Cached Biology News:Diners may be willing to pay more to eat at 'green' restaurants 2Diners may be willing to pay more to eat at 'green' restaurants 3UTHealth professor to receive service award from American Society for Microbiology 2CCNY professor gets grant to develop 'artificial blood' 2
... The membrane filters suitable for use in the ... top of each filter, in a specially designed ... special pleating of the band of membrane filter ... dispensed. The shape of the sealed band guarantees ...
... PRKAR2 cAMP is a signaling molecule ... cAMP exerts its effects by activating the ... signal through phosphorylation of different target proteins. ... tetramer composed of two regulatory and two ...
... The model 55S Rocking Shaker ... gels and blotted membranes. The very ... adjustable degree of tilt provide a ... washes over gels and blotted membranes ...
...
Biology Products: